Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products-Reference-Cited by-同舟云学术

Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products

Published:2017-11-07 Issue:1 Volume:10 Page:166-176
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Hassett Brian¹,Scheinberg Morton²,Castañeda-Hernández Gilberto³,Li Mengtao⁴,Rao Uppuluri R K⁵,Singh Ena⁶,Mahgoub Ehab⁷,Coindreau Javier⁸,O'Brien Julie⁹,Vicik Steven M¹⁰,Fitzpatrick Brian¹

Affiliation:

1. Pfizer, Biotechnology & Aseptic Sciences Group, Dublin, Ireland

2. Department of Rheumatology, Hospital Albert Einstein and Hospital AACD, São Paulo, Brazil

3. Departamento de Farmacología, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico

4. Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China

5. Department of Rheumatology, Sri Deepti Rheumatology Center, Hyderabad, Telangana, India

6. Pfizer, Inflammation & Immunology Global Medical Affairs, Collegeville, PA, USA

7. Pfizer, Inflammation & Immunology Regional Medical Affairs, Collegeville, PA, USA

8. Pfizer, Biosimilars Global Medical Affairs, New York, NY, USA

9. Pfizer, Europe & International Regulatory Policy, Dublin, Ireland

10. Pfizer, Global Supply, Andover, MA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2017.1387346

Reference55 articles.

1. Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

2. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

3. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis

4. Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

5. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2010 [accessed 2016 June 23]. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selecting the best-value biosimilar in emerging countries;Exploration of Musculoskeletal Diseases;2024-09-14

2. Efficacy, safety and immunogenicity of the biosimilar etanercept compared to the reference formulation original etanercept in patients with rheumatoid arthritis: An open-label, randomized, comparative, multicenter study;Medicine;2024-07-26

3. Tumor necrosis factor-α inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series;Journal of International Medical Research;2024-01

4. Why is there no biosimilar of Erbitux®?;Journal of Pharmaceutical and Biomedical Analysis;2023-09

5. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms;Frontiers in Bioengineering and Biotechnology;2022-02-09